Compare · ELV vs LH
ELV vs LH
Side-by-side comparison of Elevance Health Inc. (ELV) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $84.37B, about 4.0x LH ($20.98B).
- Over the past year, ELV is up 3.8% and LH is down 2.3% - ELV leads by 6.1 points.
- ELV has been more active in the news (8 items in the past 4 weeks vs 6 for LH).
- LH has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Labcorp Holdings Inc.
- Price
- $388.60-0.68%
- $255.88-1.41%
- Market cap
- $84.37B
- $20.98B
- 1M return
- -3.47%
- +1.08%
- 1Y return
- +3.76%
- -2.31%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 6
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ELV
- SEC Form 11-K filed by Elevance Health Inc.
- SEC Form 11-K filed by Elevance Health Inc.
- Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
- CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)
- Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
- Director Dixon Robert L Jr sold $60,667 worth of shares (151 units at $401.77), decreasing direct ownership by 1% to 10,734 units (SEC Form 4)
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
Latest LH
- EVP, Chief Legal Officer Kyle Kathryn W sold $201,084 worth of shares (762 units at $263.89) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 3,813 units (SEC Form 4)
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Present at the Jefferies Global Healthcare Conference
- Labcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Labcorp Holdings Inc.
- Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
- President & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)
- Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems